Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson

PHASE4CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Ischemic Heart Disease
Interventions
DRUG

Regadenoson

Regadenoson 400 micrograms will be administered in a single IV bolus (\<10 seconds) via an antecubital cannula and followed by 5 mL of saline flush. 10-20 seconds after the regadenoson is administered, 10 mCi of 13N-ammonia as a bolus, and 0.075 mmol/Kg of gadobenate dimeglumine MR contrast agent at a rate of 5 mL/sec followed by a 15 mL normal saline flush will be administered simultaneous, each into an antecubital vein, and a 15 min list-mode PET acquisition will be acquired simultaneously with the MR perfusion imaging.

Trial Locations (1)

63110

Center for Clinical Imaging Research at Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT01779869 - Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson | Biotech Hunter | Biotech Hunter